Drug news
BOLERO-2 trail shows bonbe improvement with Afinitor/Aromasin combination in Breast Cancer
A review of BOLERO-2 Phase III trial in oestrogen receptor positive post menopausal women showed that the combination of Afinitor
(everolimus) plus Aromasin (exemestane) significantly improved bone strength and reduced the chance of cancer spreading to the bone. The trial had earlier shown that this drug combination significantly improved outcomes stopping tumour growth for nearly 11 months
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.